Lasa Supergenerics Discloses Related Party Transactions for Q4FY26
Lasa Supergenerics Limited disclosed related party transactions for the quarter and year ended March 31, 2026. Total transactions amounted to ₹618 crore, with ₹35.36 crore in interest. Transactions include remuneration, sitting fees, and donations to related parties.
Disclosure of related party transactions is a standard regulatory requirement and typically does not have a significant immediate impact on the company's stock unless unusual or substantial transactions are revealed.
The announcement is a routine regulatory filing disclosing related party transactions and does not contain any information that would significantly impact the company's stock price or future performance in a positive or negative way.
Lasa Supergenerics Limited has submitted a disclosure of related party transactions for the quarter and year ended March 31, 2026, as per Regulation 23(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. The disclosure includes transactions with promoters, directors, and their associated entities.
Key related party transactions include remuneration to directors and key management personnel, sitting fees for independent directors, and a donation to Dr. Omkar Herlekar Foundation. The total value of transactions for the reporting period amounts to ₹618 crore, with interest paid totaling ₹35.36 crore. Specific details of loans, inter-corporate deposits, advances, or investments are also provided in the annexure to the filing.
The filing was made on Friday, May 29, 2026, and submitted to both the BSE Limited and the National Stock Exchange of India Limited.
What to do with a filing like this
Lasa Supergenerics Limited filed this with the NSE as a statutory disclosure, categorised under related party transactions. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lasa Supergenerics Limited. Read the original for the full detail.